NCT02639858 is a Phase 2 clinical trial of Docetaxel-PM in Head and Neck Squamous Cell Carcinoma, sponsored by Samyang Biopharmaceuticals Corporation.

Who is sponsoring NCT02639858?

NCT02639858 is sponsored by Samyang Biopharmaceuticals Corporation.

What drugs are being tested in NCT02639858?

Interventions in NCT02639858: Docetaxel-PM.

What condition does NCT02639858 study?

NCT02639858 studies Head and Neck Squamous Cell Carcinoma.

Is NCT02639858 still recruiting?

NCT02639858 is currently status unknown. Last updated 27 April 2017.

Last reviewed 2017-04-27 · How we verify

NCT02639858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study to Evaluate the Efficacy and Safety of Docetaxel-PM in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 27 April 2017

What this trial tests

Phase 2 trial testing Docetaxel-PM in Head and Neck Squamous Cell Carcinoma in 31 participants. Status unknown.

Timeline

1 October 2015

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	Samyang Biopharmaceuticals Corporation
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	1 October 2015
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	1 location across South Korea

Drugs / interventions tested

Docetaxel-PM — full drug profile →

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

Samyang Biopharmaceuticals Corporation — full company profile →

Who can join

Adults 20 to 79, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response rate as assessed by RECIST v1.1
Time frame: 2 years
Response is confirmed at least 4 weeks later. Assessment: every 6 weeks (treatment period), every 2 months (follow-up period)

Sponsor's own description

A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticles in the clinic: An update.
Anselmo AC, Mitragotri S. · · 2019 · cited 976× · PMID 31572799 · DOI 10.1002/btm2.10143
Nanoparticles in the clinic.
Anselmo AC, Mitragotri S. · · 2016 · cited 773× · PMID 29313004 · DOI 10.1002/btm2.10003
Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.
Hwang D, Ramsey JD, Kabanov AV. · · 2020 · cited 376× · PMID 32980449 · DOI 10.1016/j.addr.2020.09.009
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
Stimuli-responsive polymeric micelles for drug delivery and cancer therapy.
Zhou Q, Zhang L, Yang T, Wu H. · · 2018 · cited 195× · PMID 29849457 · DOI 10.2147/ijn.s158696
Progress in Polymeric Micelles for Drug Delivery Applications.
Kotta S, Aldawsari HM, Badr-Eldin SM, Nair AB, et al · · 2022 · cited 113× · PMID 36015262 · DOI 10.3390/pharmaceutics14081636
Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy.
Chang D, Ma Y, Xu X, Xie J, et al · · 2021 · cited 69× · PMID 34249894 · DOI 10.3389/fbioe.2021.707319
Polymeric Micellar Systems-A Special Emphasis on "Smart" Drug Delivery.
Negut I, Bita B. · · 2023 · cited 66× · PMID 36986837 · DOI 10.3390/pharmaceutics15030976

Verify or expand the search:

Other trials of Docetaxel-PM

Trials testing the same drug.

NCT03585673 — Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma · Phase 2 · unknown

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Samyang Biopharmaceuticals Corporation trials

Trials by the same sponsor.

NCT07467239 — A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds · NA · recruiting
NCT06961448 — A Study in Adults Evaluating Polycaprolactone Microsphere Filler for Treatment of Moderate to Severe Nasolabial Folds · NA · not yet recruiting
NCT06402058 — A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement · NA · not yet recruiting
NCT06295172 — A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement · NA · not yet recruiting
NCT06093321 — A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02639858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samyang Biopharmaceuticals Corporation
Last refreshed: 27 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02639858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing